评估肺炎链球菌中检测氟喹诺酮耐药机制的药敏试验。
Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
作者信息
Richardson D C, Bast D, McGeer A, Low D E
机构信息
Toronto Medical Laboratories and Mount Sinai Hospital Department of Microbiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
出版信息
Antimicrob Agents Chemother. 2001 Jun;45(6):1911-4. doi: 10.1128/AAC.45.6.1911-1914.2001.
Abstract
To determine if susceptibility testing of Streptococcus pneumoniae could detect those isolates that had one of the recognized mechanisms of fluoroquinolone resistance, 101 isolates were selected; the levofloxacin MIC for 28 of these isolates was > or =4 microg/ml. Only isolates with both parC and gyrA mutations or with no recognized resistance mechanisms were reliably identified by using these results. Isolates with only a parC mutation could not be detected reliably using any susceptibility testing method.
摘要
为了确定肺炎链球菌的药敏试验能否检测出具有公认氟喹诺酮耐药机制之一的分离株，选取了101株分离株；其中28株分离株的左氧氟沙星最低抑菌浓度（MIC）≥4μg/ml。只有同时具有parC和gyrA突变或没有公认耐药机制的分离株才能通过这些结果可靠地鉴定出来。使用任何药敏试验方法都无法可靠地检测出仅具有parC突变的分离株。
相似文献
1
Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Jun;45(6):1911-4. doi: 10.1128/AAC.45.6.1911-1914.2001.
2
Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Antimicrob Agents Chemother. 2004 Oct;48(10):3954-8. doi: 10.1128/AAC.48.10.3954-3958.2004.
3
Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.
Antimicrob Agents Chemother. 2002 Mar;46(3):680-8. doi: 10.1128/AAC.46.3.680-688.2002.
4
DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810.
5
Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2001 Dec;45(12):3517-23. doi: 10.1128/AAC.45.12.3517-3523.2001.
6
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
7
Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Microb Drug Resist. 2003 Spring;9(1):17-24. doi: 10.1089/107662903764736300.
8
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.
Emerg Infect Dis. 2003 Jul;9(7):833-7. doi: 10.3201/eid0907.020589.
9
Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Antimicrob Agents Chemother. 1996 Nov;40(11):2505-10. doi: 10.1128/AAC.40.11.2505.
10
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Antimicrob Agents Chemother. 1997 Feb;41(2):471-4. doi: 10.1128/AAC.41.2.471.
引用本文的文献
1
Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?
Can Fam Physician. 2006 Oct;52(10):1236-42.
2
Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.
Antimicrob Agents Chemother. 2006 Jun;50(6):2098-105. doi: 10.1128/AAC.00198-06.
3
New real-time PCR assay using locked nucleic acid probes to assess prevalence of ParC mutations in fluoroquinolone-susceptible Streptococcus pneumoniae isolates from France.
Antimicrob Agents Chemother. 2006 Apr;50(4):1594-8. doi: 10.1128/AAC.50.4.1594-1598.2006.
4
Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2006 Feb;50(2):572-9. doi: 10.1128/AAC.50.2.572-579.2006.
5
Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002.
Antimicrob Agents Chemother. 2004 Sep;48(9):3636-9. doi: 10.1128/AAC.48.9.3636-3639.2004.
6
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.
Antimicrob Agents Chemother. 2004 Sep;48(9):3305-11. doi: 10.1128/AAC.48.9.3305-3311.2004.
7
Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.
Emerg Infect Dis. 2003 Jul;9(7):833-7. doi: 10.3201/eid0907.020589.
8
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 2003 Aug;47(8):2606-14. doi: 10.1128/AAC.47.8.2606-2614.2003.
9
Maintaining fluoroquinolone class efficacy: review of influencing factors.
Emerg Infect Dis. 2003 Jan;9(1):1-9. doi: 10.3201/eid0901.020277.
10
Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000.
Antimicrob Agents Chemother. 2002 May;46(5):1295-301. doi: 10.1128/AAC.46.5.1295-1301.2002.
本文引用的文献
1
The new fluoroquinolones: A critical review.
Can J Infect Dis. 1999 May;10(3):207-38. doi: 10.1155/1999/378394.
2
THE SPECIFIC POLYSACCHARIDE CONTENT OF PNEUMONIC LUNGS.
J Exp Med. 1942 Dec 1;76(6):505-10. doi: 10.1084/jem.76.6.505.
3
Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
Antimicrob Agents Chemother. 2000 Nov;44(11):3049-54. doi: 10.1128/AAC.44.11.3049-3054.2000.
4
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.
Antimicrob Agents Chemother. 2000 Aug;44(8):2160-5. doi: 10.1128/AAC.44.8.2160-2165.2000.
5
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
J Antimicrob Chemother. 2000 May;45(5):583-90. doi: 10.1093/jac/45.5.583.
6
Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Antimicrob Agents Chemother. 1999 Aug;43(8):2000-4. doi: 10.1128/AAC.43.8.2000.
7
Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.
N Engl J Med. 1999 Jul 22;341(4):233-9. doi: 10.1056/NEJM199907223410403.
8
Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong.
Antimicrob Agents Chemother. 1999 May;43(5):1310-3. doi: 10.1128/AAC.43.5.1310.
9
Primary targets of fluoroquinolones in Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1999 Feb;43(2):410-2. doi: 10.1128/AAC.43.2.410.
10
Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329.
Zotero 插件